Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics.
- Müller C Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSI, Switzerland.
- Vermeulen C Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSI, Switzerland.
- Köster U Institut Laue-Langevin, Grenoble, France.
- Johnston K Physics Department, ISOLDE/CERN, Geneva, Switzerland.
- Türler A Laboratory of Radiochemistry, Paul Scherrer Institut, Villigen-PSI, Switzerland.
- Schibli R Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSI, Switzerland.
- van der Meulen NP Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSI, Switzerland.
- 2018-03-23
Published in:
- EJNMMI radiopharmacy and chemistry. - 2017
English
149Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T1/2 = 4.1 h), low α-energy (3.97 MeV, Iα = 16.7 %), absence of α-emitting daughters and stable coordination via DOTA are favorable features for potential clinical application. In this letter, we wish to highlight the unique characteristics of 149Tb for PET imaging, based on its positron emission (Eβ+mean = 730 keV, Iβ+ = 7.1 %) in addition to it's a therapeutic value. To this end, a preclinical study with a tumor-bearing mouse is presented. The perspective of alpha-PET makes 149Tb highly appealing for radiotheragnostic applications in future clinical trials.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1186/s41181-016-0008-2
- PMID 29564382
- Persistent URL
- https://folia.unifr.ch/global/documents/99661
Statistics
Document views: 31
File downloads:
- Full-text: 0